GLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing Matters

GLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing Matters

(MedPage Today) -- SAN FRANCISCO -- In order to maximize weight loss, a GLP-1 receptor agonist may be needed both before and after bariatric surgery, a retrospective analysis found. In 568 patients who underwent bariatric surgery, those who...

GLP-1 Reimbursement and Access Debates: The Battle Over Coverage Criteria, Prior Authorization, and Equity

A single prior-authorization denial can derail a patient’s treatment plan. In 2025, the soaring use of GLP-1 receptor agonists such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) has invigorated clinical outcomes for obesity and type 2 diabetes, yet payers are tightening the criteria for coverage, imposing onerous prior authorizations, and raising profound questions about equitable care. Clinical Promise Meets Payer Prudence Randomiz…

Can Nonresponders to Antiobesity Medicines Be Predicted?

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or another, but more validation is needed.